ASMB - Assembly Biosciences Inc Stock Price, Fair Value and News

14.84USD+0.12 (+0.82%)Market Closed

Market Summary

USD14.84+0.12

Market Closed

0.82%

ASMB Stock Price

View Fullscreen

ASMB RSI Chart

ASMB Valuation

Market Cap

81.8M

Price/Earnings (Trailing)

-1.59

Price/Sales (Trailing)

11.42

EV/EBITDA

-1.04

Price/Free Cashflow

2.97

ASMB Price/Sales (Trailing)

ASMB Profitability

EBT Margin

-854.32%

Return on Equity

-157.53%

Return on Assets

-42.84%

Free Cashflow Yield

33.66%

ASMB Fundamentals

ASMB Revenue

Revenue (TTM)

7.2M

Rev. Growth (Yr)

1.0K%

Rev. Growth (Qtr)

8.46%

ASMB Earnings

Earnings (TTM)

-51.4M

Earnings Growth (Yr)

52.1%

Earnings Growth (Qtr)

17.2%

Breaking Down ASMB Revenue

Last 7 days

10.8%

Last 30 days

14.9%

Last 90 days

29.7%

Trailing 12 Months

22.4%

How does ASMB drawdown profile look like?

ASMB Financial Health

Current Ratio

3.02

ASMB Investor Care

Shares Dilution (1Y)

26.93%

Diluted EPS (TTM)

-10.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	6.9M	0	7.0M	7.2M
2022	6.4M	0	6.6M	6.7M
2021	54.8M	0	30.5M	6.3M
2020	16.2M	52.5M	82.8M	79.1M
2019	15.1M	15.0M	14.9M	16.0M
2018	11.9M	12.8M	14.4M	14.8M
2017	3.0M	6.0M	7.5M	9.0M
2016	1.7M	1.9M	1.8M	1.5M
2015	185.7K	360.0K	827.5K	1.2M
2014	192.7K	184.3K	176.0K	167.7K
2013	0	0	0	201.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Assembly Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 30, 2024	okazaki jason a	sold	-19,937	12.7068	-1,569	ceo and president
Apr 30, 2024	white nicole s	sold	-15,947	12.7068	-1,255	chief manufacturing officer
Apr 29, 2024	okazaki jason a	acquired	-	-	4,166	ceo and president
Apr 29, 2024	white nicole s	acquired	-	-	3,333	chief manufacturing officer
Apr 29, 2024	delaney william e iv	acquired	-	-	3,333	chief scientific officer
Apr 01, 2024	white nicole s	sold	-2,575	13.0719	-197	chief manufacturing officer
Apr 01, 2024	bjorkquist jeanette m	sold	-1,490	13.0719	-114	principal accounting officer

Which funds bought or sold ASMB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-36,821	-	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	sold off	-100	-27,227	-	-%
May 15, 2024	BARCLAYS PLC	sold off	-100	-29,000	-	-%
May 15, 2024	MORGAN STANLEY	new	-	32,877	32,877	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-25,144	-	-%
May 15, 2024	HSBC HOLDINGS PLC	sold off	-100	-9,417	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-24.00	-	-%
May 15, 2024	STATE STREET CORP	sold off	-100	-119,189	-	-%
May 15, 2024	STATE STREET CORP	new	-	161,050	161,050	-%
May 15, 2024	BARCLAYS PLC	new	-	40,000	40,000	-%

Are Funds Buying or Selling ASMB?

Are funds buying ASMB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ASMB

No. of Funds

Unveiling Assembly Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 22, 2023	schornstein alexander	11.51%	7,564,292	SC 13D/A
Nov 03, 2023	schornstein alexander	10.9%	7,164,292	SC 13D/A
Oct 31, 2023	schornstein alexander	-	0	SC 13D
Oct 25, 2023	gilead sciences, inc.	19.9%	13,073,668	SC 13D
Feb 14, 2023	deep track capital, lp	3.76%	1,833,437	SC 13G/A
Feb 15, 2022	armistice capital, llc	4.2%	2e+06	SC 13G/A
Feb 14, 2022	consonance capital management lp	-	0	SC 13G/A
Feb 14, 2022	deep track capital, lp	6.27%	3e+06	SC 13G/A
Feb 09, 2022	vanguard group inc	4.61%	2,205,053	SC 13G/A
Oct 12, 2021	deep track capital, lp	5.32%	2,393,876	SC 13G

Recent SEC filings of Assembly Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 01, 2024	4	Insider Trading
May 01, 2024	4	Insider Trading
May 01, 2024	4	Insider Trading
Apr 17, 2024	ARS	ARS
Apr 17, 2024	DEF 14A	DEF 14A
Apr 17, 2024	DEFA14A	DEFA14A
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to Assembly Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Assembly Biosciences Inc News

Latest updates

Assembly Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q1	2021Q4	2021Q3	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	8.5%	5,785,000	5,334,000	628,000	504,000	380,000	256,000	128,000	-	6,254,000	3,645,500	1,037,000	34,611,000	39,376,000	4,081,000	4,767,000	4,231,000	3,080,000	3,885,000	3,735,000	4,286,000	3,218,000
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26,861,411	30,383,786
Operating Expenses	-16.2%	16,514,000	19,714,000	15,048,000	19,559,000	22,978,000	23,401,000	23,162,000	62,889,000	25,129,000	27,258,000	40,679,000	38,630,000	32,797,000	31,775,000	33,451,000	30,224,000	22,780,000	32,221,000	30,057,000	26,861,000	30,384,000
S&GA Expenses	-100.0%	-	8,708,000	4,224,000	5,012,000	6,125,000	5,271,000	5,957,000	6,504,000	6,655,000	8,704,000	7,170,000	11,689,000	9,470,000	8,729,000	10,834,000	8,488,000	4,080,000	9,517,000	8,806,000	7,752,000	12,544,000
R&D Expenses	7.9%	11,879,000	11,006,000	10,824,000	14,547,000	16,853,000	18,130,000	17,205,000	14,747,000	18,474,000	18,554,000	33,509,000	26,941,000	23,327,000	23,046,000	22,616,500	21,736,000	18,700,000	22,704,000	21,251,000	19,109,000	17,840,000
EBITDA Margin	-0.2%	-8.49	-8.48	-13.20	-13.49	-13.79	-20.11	-20.58	-21.08	-2.01	-1.12	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-741,000	-15,000	-11,000	-7,000	1,139,000	-6,000	-34,000
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-39,418,000	-3,349,000	7,270,000	-26,655,000	-27,825,000	-25,010,000	-18,514,000	-27,059,000	-25,022,000	-21,541,000	-26,840,000
EBT Margin	0%	-8.54	-8.54	-13.28	-13.57	-13.88	-20.19	-20.67	-21.17	-2.04	-1.13	-	-	-	-	-	-	-	-	-	-	-
Net Income	17.2%	-9,077,000	-10,962,000	-14,420,000	-18,950,000	-22,395,000	-23,145,000	-23,091,000	-60,257,000	-18,803,000	-27,200,000	-39,418,000	-3,349,000	7,270,000	-26,655,000	-27,084,000	-24,995,000	-18,503,000	-27,052,000	-26,161,000	-21,535,000	-26,806,000
Net Income Margin	16.1%	-7.17	-8.55	-10.36	-12.97	-13.88	-19.97	-19.63	-20.76	-3.57	-1.14	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-125.0%	-18,378,000	73,576,000	-13,984,000	-23,428,000	-19,254,000	-19,924,000	-27,502,000	-19,380,000	-18,882,000	-36,422,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-12.4%	120	137	52.00	67.00	83.00	102	122	143	163	191	249	262	279	283	306	295	313	340	223	242	259
Current Assets	-12.4%	117	134	50.00	64.00	80.00	97.00	115	124	131	154	188	206	222	224	246	235	257	283	165	183	201
Cash Equivalents	-5.5%	19.00	20.00	27.00	22.00	43.00	52.00	55.00	43.00	51.00	46.00	71.00	60.00	78.00	59.00	58.00	97.00	42.00	47.00	25.00	34.00	29.00
Net PPE	-4.7%	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00
Liabilities	-8.8%	87.00	96.00	10.00	12.00	13.00	19.00	19.00	19.00	16.00	22.00	24.00	30.00	32.00	43.00	36.00	28.00	62.00	67.00	67.00	67.00	69.00
Current Liabilities	-1.2%	39.00	39.00	7.00	9.00	10.00	16.00	15.00	15.00	11.00	16.00	15.00	14.00	14.00	24.00	17.00	17.00	21.00	24.00	21.00	20.00	25.00
Shareholder's Equity	-20.7%	33.00	41.00	42.00	55.00	70.00	83.00	102	124	147	169	225	232	247	241	271	267	252	273	156	175	190
Retained Earnings	-1.2%	-794	-785	-774	-760	-743	-724	-702	-678	-654	-631	-571	-552	-528	-501	-462	-458	-466	-439	-412	-387	-368
Additional Paid-In Capital	0.1%	828	827	817	816	814	808	805	804	802	801	796	784	776	742	733	726	718	713	569	562	559
Accumulated Depreciation	-100.0%	-	0.00	-	-	-	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0%	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	60.00	-	-	-	101	-	-	-	168	-	-	-	757	-	-	-	333	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-124.9%	-18,364	73,647	-13,848	-13,628	-23,428	-19,254	-19,822	-17,885	-27,502	-19,362	-18,882	-21,808	-33,344	-25,269	10,646	-23,116	-25,218	-20,528	-18,595	-21,005	-23,939
Share Based Compensation	-22.9%	739	959	1,135	1,190	1,835	2,013	1,556	1,581	1,443	1,945	1,592	1,986	-286	3,747	6,048	7,134	4,924	6,509	5,404	2,068	6,577
Cashflow From Investing	119.3%	17,272	-89,654	18,881	-8,365	10,000	16,562	31,432	9,597	33,049	-8,484	20,070	-3,087	18,016	20,715	-49,887	76,549	20,693	-95,022	7,819	25,450	11,435
Cashflow From Financing	-100.0%	-	9,192	-	134	4,492	437	-	177	-	2,713	10,055	6,159	34,137	5,687	843	950	119	137,415	1,385	706	140

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ASMB Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue from a related party	$ 5,785	$ 0
Operating expenses
Research and development	11,879	14,547
General and administrative	4,635	5,012
Total operating expenses	16,514	19,559
Loss from operations	(10,729)	(19,559)
Other income
Interest and other income, net	1,652	609
Total other income	1,652	609
Net loss	(9,077)	(18,950)
Other comprehensive loss
Unrealized (loss) gain on marketable securities	(158)	290
Comprehensive loss	$ (9,235)	$ (18,660)
Net loss per share, basic	$ (1.66)	$ (4.46)
Net loss per share, diluted	$ (1.66)	$ (4.46)
Weighted average common shares outstanding, basic	5,483,313	4,251,037
Weighted average common shares outstanding, diluted	5,483,313	4,251,037

ASMB Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 18,749	$ 19,841
Marketable securities	94,227	110,406
Accounts receivable from collaboration	43	43
Prepaid expenses and other current assets	4,149	3,497
Total current assets	117,168	133,787
Property and equipment, net	367	385
Operating lease right-of-use (ROU) assets	2,036	2,339
Other assets	312	312
Total assets	119,883	136,823
Current liabilities
Accounts payable	727	461
Accrued research and development expenses	2,059	885
Other accrued expenses	2,051	5,744
Deferred revenue from a related party - short-term	32,771	30,915
Operating lease liabilities - short-term	1,145	1,220
Total current liabilities	38,753	39,225
Deferred revenue from a related party - long-term	47,738	55,379
Operating lease liabilities - long-term	791	1,122
Total liabilities	87,282	95,726
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 5,482,752 shares issued and outstanding as of March 31, 2024 and December 31, 2023	5	5
Additional paid-in capital	827,660	826,921
Accumulated other comprehensive loss	(239)	(81)
Accumulated deficit	(794,825)	(785,748)
Total stockholders' equity	32,601	41,097
Total liabilities and stockholders' equity	$ 119,883	$ 136,823

About Assembly Biosciences Inc

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

CEO	Mr. Jason A. Okazaki
WEBSITE	assemblybio.com
INDUSTRY	Biotechnology
EMPLOYEES	70

Assembly Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Assembly Biosciences Inc? What does ASMB stand for in stocks?

ASMB is the stock ticker symbol of Assembly Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Assembly Biosciences Inc (ASMB)?

As of Fri May 17 2024, market cap of Assembly Biosciences Inc is 81.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ASMB stock?

You can check ASMB's fair value in chart for subscribers.

What is the fair value of ASMB stock?

You can check ASMB's fair value in chart for subscribers. The fair value of Assembly Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Assembly Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ASMB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Assembly Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether ASMB is over valued or under valued. Whether Assembly Biosciences Inc is cheap or expensive depends on the assumptions which impact Assembly Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ASMB.

What is Assembly Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ASMB's PE ratio (Price to Earnings) is -1.59 and Price to Sales (PS) ratio is 11.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ASMB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Assembly Biosciences Inc's stock?

In the past 10 years, Assembly Biosciences Inc has provided -0.118 (multiply by 100 for percentage) rate of return.